A Clear Verdict Based On Current Evidence To date, there are no peer-reviewed human trials demonstrating that consumer GLP-1 patches activate GLP-1 receptors, support clinically meaningful appetite changes, or influence blood sugar through the same mechanisms as prescription medications
A BMI of 30 in a white individual carries equivalent diabetes risk to a BMI of approximately 23.9 in a South Asian individual and 26.9 in a Chinese individual
In some people it can expand without major metabolic harm
[1] [2] These medications include semaglutide (Ozempic, Wegovy, Rybelsus), dulaglutide (Trulicity), liraglutide (Victoza, Saxenda), and others
Less common and long-term GLP-1 drug side effects Not all GLP-1 drug side effects are created equal
One area where we frequently receive questions is the difference between GLP-1 and Ozempic, two closely related but fundamentally different terms you might encounter during your treatment journey